Masteron is indicated for treatment of breast cancer in elderly post-menopausal as part of aspecific immunotherapy.
Drostanolone, or dromostanolone, is an anabolic–androgenic steroid (AAS) of the dihydrotestosterone (DHT) group which was never marketed. An androgen ester prodrug of drostanolone, drostanolone propionate, was formerly used in the treatment of breast cancer in women under brand names such as Drolban, Masteril, and Masteron. This ester has also been used non-medically for physique- or performance-enhancing purposes.
Masteron or Drostanolone Propionate is a dihydrotestosterone derived anabolic steroid. Specifically, Masteron is the hormone that has been structurally altered by the addition of a methyl group at the carbon 2 position, This protects the hormone from the metabolic breakdown by the 3-hydroxysteroid dehydrogenase enzyme, which is found in the skeletal muscle. It also greatly increases the hormone’s anabolic nature. This simple structural change is all it takes to create Drostanolone, and from here the small/short Propionate ester is attached in order to control the hormone’s release time.
The principal clinical indication of drostanolone propionate in the United States as well as international markets was the treatment of advanced inoperable breast cancer in women.
Hormonal treatment is part of the complex therapy for some kind of tumors, particularly the ones associated with hormone-active tissues like breast or prostate cancer. Some types of breast cancer cells, expressing estrogen receptors (called ER+ cancers), use estrogen for their growth and dissemination. That is why drugs that block estrogen receptors or decrease their expression on the cell membrane, antiestrogens, could limit the tumor spread and size. Drostanolone propionate has been FDA approved as an antiestrogenic drug for the treatment of breast cancer. By the time of its release, there were not many alternatives for patients suffering from breast cancer and drostanolone propionate was a revolution for these patients. As it has lower androgenic rate compared to testosterone, the risk of virilization is much lighter. Due to this fact, women, who usually do not respond well to any AAS, were having much greater chance to survive cancer. Drostanolone propionate can also be used for breast tumors that do not respond well to other treatments or also as palliative care for advanced incurable tumors. The effects of the product depend of course on the dose and period of administration. The risk of virilization becomes greater with high doses and continuous administration period.